Literature DB >> 8609245

Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a).

V Mooser1, M C Seabra, M Abedin, K T Landschulz, S Marcovina, H H Hobbs.   

Abstract

Apo(a) is a large glycoprotein of unknown function that circulates in plasma as part of lipoprotein(a). Apo(a) is structurally related to plasminogen and contains at least 10 kringle (K)4 repeats (type 1-10), a K5 repeat and sequences similar to the protease domain of plasminogen. Plasminogen generates two biologically active peptides: plasmin and angiostatin, a kringle-containing peptide. As a first step in determining if apo(a) generates a similar kringle-containing peptide, human urine was immunologically examined. Fragments ranging in size from 85 to 215 kD were immunodetected using antibodies directed against epitopes in the K4-type 2 repeat, but not the K4-type 9 repeat or protease domain, NH2-terminal sequence analysis revealed sequences specific for the K4-type 1 repeat, confirming that the fragments are from the NH2 terminus of the K4 array. The amount of urinary apo(a) rose in proportion to the plasma lipoprotein(a) concentration. Even individuals with trace to no apo(a) in plasma had immunodetectable apo(a) fragments in their urine. Intravenous administration of the human urinary apo(a) into mice resulted in the urine. These findings suggest that the apo(a) fragments found in urine are formed extrarenally and then excreted by the kidney.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8609245      PMCID: PMC507126          DOI: 10.1172/JCI118487

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Characterization of polymerase chain reaction amplification of specific alleles.

Authors:  G Sarkar; J Cassady; C D Bottema; S S Sommer
Journal:  Anal Biochem       Date:  1990-04       Impact factor: 3.365

2.  Apolipoprotein(a) size heterogeneity is related to variable number of repeat sequences in its mRNA.

Authors:  M L Koschinsky; U Beisiegel; D Henne-Bruns; D L Eaton; R M Lawn
Journal:  Biochemistry       Date:  1990-01-23       Impact factor: 3.162

3.  Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation.

Authors:  G L Cushing; J W Gaubatz; M L Nava; B J Burdick; T M Bocan; J R Guyton; D Weilbaecher; M E DeBakey; G M Lawrie; J D Morrisett
Journal:  Arteriosclerosis       Date:  1989 Sep-Oct

4.  cDNA sequence of human apolipoprotein(a) is homologous to plasminogen.

Authors:  J W McLean; J E Tomlinson; W J Kuang; D L Eaton; E Y Chen; G M Fless; A M Scanu; R M Lawn
Journal:  Nature       Date:  1987 Nov 12-18       Impact factor: 49.962

5.  Immunochemical heterogeneity of human plasma apolipoprotein B. I. Apolipoprotein B binding of mouse hybridoma antibodies.

Authors:  L K Curtiss; T S Edgington
Journal:  J Biol Chem       Date:  1982-12-25       Impact factor: 5.157

6.  Rhesus monkey apolipoprotein(a). Sequence, evolution, and sites of synthesis.

Authors:  J E Tomlinson; J W McLean; R M Lawn
Journal:  J Biol Chem       Date:  1989-04-05       Impact factor: 5.157

7.  Extraction of lipoprotein(a), apo B, and apo E from fresh human arterial wall and atherosclerotic plaques.

Authors:  T Reblin; N Meyer; C Labeur; D Henne-Bruns; U Beisiegel
Journal:  Atherosclerosis       Date:  1995-03       Impact factor: 5.162

8.  Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients.

Authors:  M Rath; A Niendorf; T Reblin; M Dietel; H J Krebber; U Beisiegel
Journal:  Arteriosclerosis       Date:  1989 Sep-Oct

9.  Lipoprotein(a) in nonhuman primates. Presence and characteristics of Lp(a) immunoreactive materials using anti-human Lp(a) serum.

Authors:  K Makino; A Abe; S Maeda; A Noma; M Kawade; O Takenaka
Journal:  Atherosclerosis       Date:  1989-07       Impact factor: 5.162

10.  Lipoprotein[a] is the major apoB-containing lipoprotein in the plasma of a hibernator, the hedgehog (Erinaceus europaeus).

Authors:  P M Laplaud; L Beaubatie; S C Rall; G Luc; M Saboureau
Journal:  J Lipid Res       Date:  1988-09       Impact factor: 5.922

View more
  8 in total

Review 1.  Lipoprotein(a) and coronary heart disease risk.

Authors:  S M Marcovina; R A Hegele; M L Koschinsky
Journal:  Curr Cardiol Rep       Date:  1999-07       Impact factor: 2.931

2.  The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor.

Authors:  K M Argraves; K F Kozarsky; J T Fallon; P C Harpel; D K Strickland
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

3.  Plasma apolipoprotein(a) co-deposits with fibrin in inflammatory arthritic joints.

Authors:  N Busso; J Dudler; R Salvi; V Péclat; V Lenain; S Marcovina; R Darioli; P Nicod; A K So; V Mooser
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

4.  Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine.

Authors:  V Mooser; S M Marcovina; A L White; H H Hobbs
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

Review 5.  Lipoprotein(a) beyond the kringle IV repeat polymorphism: The complexity of genetic variation in the LPA gene.

Authors:  Stefan Coassin; Florian Kronenberg
Journal:  Atherosclerosis       Date:  2022-05       Impact factor: 6.847

Review 6.  Lipoprotein(a) metabolism: potential sites for therapeutic targets.

Authors:  Jane Hoover-Plow; Menggui Huang
Journal:  Metabolism       Date:  2012-10-04       Impact factor: 8.694

Review 7.  The role of lipoprotein (a) in chronic kidney disease.

Authors:  Jemma C Hopewell; Richard Haynes; Colin Baigent
Journal:  J Lipid Res       Date:  2018-01-29       Impact factor: 5.922

8.  In-Depth Mapping of the Urinary N-Glycoproteome: Distinct Signatures of ccRCC-related Progression.

Authors:  Lucia Santorelli; Giulia Capitoli; Clizia Chinello; Isabella Piga; Francesca Clerici; Vanna Denti; Andrew Smith; Angelica Grasso; Francesca Raimondo; Marco Grasso; Fulvio Magni
Journal:  Cancers (Basel)       Date:  2020-01-18       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.